Lira-cel Phase I Safety Signal Encouraging But Solid Tumor CAR-T Approval Remains Uncharted Territory

Anixa Treats First Patient in Highest Dose Cohort for Ovarian CAR-T

Anixa Biosciences has treated the first patient in the fifth and highest dose cohort of its Phase I clinical trial for liraltagene autoleucel (lira-cel), a CAR-T therapy for recurrent ovarian cancer. The dose-escalation study, conducted at Moffitt Cancer Center, is primarily assessing safety and tolerability, with early efficacy signals also being monitored. Notably, no dose-limiting toxicities have been observed across the study to date. Five participants have already surpassed one year of survival post-treatment, with individual survival times ranging from 13 to 28 months, which is a significant improvement for patients who typically face a prognosis of weeks.

• Anixa Biosciences has successfully progressed its Phase I dose-escalation trial for lira-cel to the fifth and highest dose cohort, administering a 1x10^7/kg CAR-positive cells dose to the first patient after lymphodepletion. A key achievement is the absence of any dose-limiting toxicities observed across all cohorts to date, indicating a favorable safety profile for this novel CAR-T therapy in a challenging patient population.
• Despite the Phase I trial's primary focus on safety, encouraging early efficacy signals have emerged. Five patients with highly pre-treated recurrent ovarian cancer have achieved survival times exceeding one year, with reported durations of approximately 28, 20, 17, 17, and 13 months. This is particularly significant given that patients with recurrent ovarian cancer typically have a prognosis of only weeks, highlighting the potential impact of lira-cel.
• Liraltagene autoleucel (lira-cel) is engineered to target the follicle-stimulating hormone receptor (FSHR), which is predominantly found on ovarian tumor cells and tumor vasculature, minimizing off-target effects on normal tissues. The trial specifically enrolls adult women suffering from recurrent ovarian cancer who have undergone at least two prior therapies, addressing a critical unmet need for effective treatments in this severely ill patient group.

Liraltagene Autoleucel: Promising Safety and Early Efficacy Signals

Published safety data for lisocabtagene maraleucel (liso-cel) across its studied indications consistently demonstrates a manageable tolerability profile, with cytokine release syndrome (CRS) and neurological events (NE) representing the most clinically significant adverse event categories. In the pivotal TRANSCEND NHL 001 study in relapsed/refractory large B-cell lymphoma (R/R LBCL), any-grade CRS occurred in 42% of patients, with grade ≥3 CRS in only 2%; any-grade NEs were reported in 30% of patients, with grade ≥3 NEs in 10%. The most common grade ≥3 hematologic toxicities were neutropenia (60%), anemia (37%), and thrombocytopenia (27%). Notably, two-year follow-up data confirmed no new safety signals emerged beyond the 90-day treatment-emergent period, with post-treatment-emergent grade ≥3 neutropenia and anemia rates declining to 7% and 6%, respectively. In the mantle cell lymphoma (MCL) cohort, a broadly similar hematologic toxicity pattern was observed — neutropenia (56%), anemia (37.5%), thrombocytopenia (25%) — alongside CRS in 61% of patients (grade 3/4: 1%) and NEs in 31% (grade 3/4: 9%). In relapsed/refractory CLL/SLL (TRANSCEND CLL 004), CRS occurred in 74% of patients (grade 3: 9%) and NEs in 39% (grade 3/4: 22%), reflecting the more heavily pretreated and immunocompromised nature of this patient population.

Comparative safety analyses position liso-cel favorably relative to other approved CAR-T constructs. A matching-adjusted indirect comparison in second-line R/R LBCL demonstrated that liso-cel was associated with significantly lower odds of grade ≥3 serious treatment-emergent adverse events (OR 0.49; 95% CI 0.27–0.90), any-grade CRS (OR 0.09; 95% CI 0.04–0.18), grade ≥3 CRS (OR 0.09; 95% CI 0.01–0.75), any-grade NEs (OR 0.08; 95% CI 0.03–0.18), and grade ≥3 NEs (OR 0.21; 95% CI 0.06–0.68) compared to axicabtagene ciloleucel (axi-cel). A meta-analysis of 1,364 patients across 15 prospective clinical trials in NHL corroborated these findings: liso-cel demonstrated the lowest CRS rate among CD19-directed CAR-T products at 43.0%, versus 70.9% for tisagenlecleucel (tisa-cel) and 87.9% for axi-cel. Rates of severe infection were elevated with axi-cel relative to both liso-cel and tisa-cel, while febrile neutropenia and all-grade infection rates did not differ significantly across products. In follicular lymphoma, liso-cel similarly showed a more favorable safety profile versus axi-cel, with significantly reduced odds of grade ≥3 CRS (OR 0.07; 95% CI 0.01–0.58), tocilizumab use (OR 0.20; 95% CI 0.09–0.44), any-grade NEs (OR 0.14; 95% CI 0.05–0.38), and infections (OR 0.42; 95% CI 0.19–0.93).

Specific clinical scenarios and emerging indications provide additional safety context. In primary mediastinal B-cell lymphoma (PMBCL) patients who received pembrolizumab prior to liso-cel infusion, the overall toxicity profile was broadly comparable to pembrolizumab-naïve patients, though one pembrolizumab-treated patient experienced fatal neurotoxicity — underscoring the need for vigilance in sequencing immunotherapies. Favorable hematologic recovery and preserved T-cell counts at leukapheresis were observed in this cohort. In a small case series of patients with Richter's transformation receiving liso-cel, no grade ≥3 CRS events were recorded, and only one patient experienced grade ≥3 immune effector cell-associated neurotoxicity syndrome (ICANS), with confirmed in vivo CAR T-cell expansion across all cases. For central nervous system lymphomas, relmacabtagene autoleucel — which expresses the same CAR construct — demonstrated CRS in 72.9% of patients (grade 3: 4.5%) and ICANS in 36.4% (grade 3: 4.5%), consistent with the toxicity range observed across other liso-cel–based programs. Collectively, these data support a differentiated and generally manageable safety profile for liso-cel, with hematologic toxicity and low-grade CRS as the predominant treatment-emergent concerns across indications.

Addressing the Critical Unmet Needs in Recurrent Ovarian Cancer

Recurrent ovarian cancer remains one of the most therapeutically challenging malignancies, with nearly all patients experiencing disease recurrence despite initial response to frontline therapy. The convergence of intrinsic tumor biology, treatment-induced resistance mechanisms, and immunosuppressive tumor microenvironments has severely constrained the efficacy of available treatment modalities.

• High recurrence burden and advanced presentation: Two-thirds of patients present with Stage III or IV disease, and the majority will suffer recurrence, require ongoing treatment, and ultimately succumb to chemotherapy-resistant disease — underscoring the systemic inadequacy of current therapeutic strategies.

• Platinum resistance as a central clinical bottleneck: Most patients with advanced disease develop resistance to platinum-based chemotherapy and subsequently relapse with poor prognosis. Epigenetic alterations, including aberrant DNA methylation, have been identified as contributing mechanisms to this resistance, further complicating re-treatment strategies.

• Tumor heterogeneity limiting long-term efficacy: The heterogeneity among ovarian cancer subtypes and the emergence of treatment resistance have raised significant concerns regarding the durable efficacy of chemotherapy, radiotherapy, and immunotherapy across the patient population.

• Immunosuppressive tumor microenvironment obstructing immunotherapy: Tumor-supported immunosuppression critically limits the immune system's capacity to mount an effective anti-tumor response. Peripheral blood mononuclear cells (PBMCs) isolated from ovarian cancer patients fail to elicit cytotoxic responses against tumor cells in vitro — a deficit not observed in immune effector cells from healthy donors.

• Myeloid-derived suppressor cells driving immune evasion: Myeloid-derived suppressor cells (MDSCs), an immature myeloid population, play a well-characterized role in immunosuppression and tumor evasion, representing a major mechanistic barrier to effective immunotherapy in this setting.

• Restricted benefit from novel targeted and immune therapies: Checkpoint inhibitors and targeted therapies benefit only a subset of patients and confer short-term protection. Chemotherapy and radiation therapy additionally cause depletion and functional impairment of immune effector cells, further undermining combination immunotherapeutic strategies.

• Limitations of cellular and antibody-based therapies in solid tumors: CAR-T cell therapy, while effective in hematologic malignancies, has demonstrated limited success against solid tumors. Reduced antigen targeting breadth and significant treatment-related toxicities diminish CAR-T efficacy, while antigen loss on tumor cells renders bispecific and trispecific antibodies ineffective.

• Persistent gaps in survival, quality of life, and therapeutic options: Current treatments for patients with clinical recurrence and drug resistance remain limited. Despite incremental advances, drug resistance and recurrence continue to represent the primary bottlenecks in ovarian cancer management, with patients still experiencing poor long-term survival due to frequent relapse — underscoring the urgent need for novel therapeutic strategies that balance efficacy with quality-of-life preservation.

FSHR: A Novel CAR-T Target for Recurrent Ovarian Cancer

Recent research into recurrent ovarian cancer has yielded a broad and mechanistically diverse landscape of emerging therapeutic targets. Among the most clinically advanced are antibody-drug conjugates (ADCs), with folate receptor-α (FRα) remaining a validated target through mirvetuximab soravtansine, which achieved a 26.7% objective response rate in FRα-positive platinum-resistant disease. TROP2-directed ADCs — including sacituzumab govitecan and datopotamab deruxtecan — have demonstrated significant efficacy with improvements in both progression-free and overall survival in advanced or treatment-resistant ovarian carcinoma. Cadherin-6 has emerged as a further ADC target of interest, with the REJOICE-Ovarian01 trial reporting remarkable efficacy, while SNAP-tag–based ADC platforms targeting EGFR, HER2, TROP2, and tissue factor (TF) have exhibited potent cytotoxicity at nanomolar concentrations. Glucocorticoid receptor modulation via relacorilant plus nab-paclitaxel (ROSELLA trial) represents an orthogonal mechanism delivering clinically meaningful survival signals in platinum-resistant disease.

On the immunotherapeutic front, the ENGOT-ov65/KEYNOTE-B96 trial established pembrolizumab plus weekly paclitaxel as a new standard of care in platinum-resistant recurrent ovarian cancer — the first immune checkpoint inhibitor regimen to demonstrate a statistically significant overall survival benefit in this setting. Beyond checkpoint blockade, mesothelin (MSLN) has been targeted by the TCR-like CAR-T construct KT127, which achieved an 80% disease control rate (95% CI: 44.4%–97.5%) with no dose-limiting toxicities, cytokine release syndrome, or immune effector cell-associated neurotoxicity syndrome in platinum-resistant advanced disease. Next-generation immunotherapeutic modalities under active investigation include bispecific T-cell engagers (BiTEs), neoantigen-based vaccines, CAR-NK cell therapies, oncolytic viruses — notably the ErbB oncogene-selective virus (ErbB-OSV), which conferred a 180% larger survival benefit when combined with chemotherapy in syngeneic models — and nanoparticle-mediated immunomodulation. Tumor microenvironment-directed strategies targeting cancer-associated fibroblasts, hypoxia-driven signaling, PI3K/AKT/mTOR axis dysregulation, and tumor-associated macrophage polarization are also gaining traction.

At the molecular target discovery level, Mendelian randomization analyses using eQTLGen and deCODE consortium data combined with large GWAS cohorts have identified PPP1R14A and PTGS2 as candidate drug targets in ovarian clear cell carcinoma, with single-cell sequencing implicating both in tumor immune regulation and molecular docking confirming druggable potential for PTGS2. Network pharmacology investigations of natural compounds such as medicarpin have highlighted ten hub genes — including CASP3, ESR1, mTOR, PIK3CA, CCND1, GSK3B, CDK4, PARP1, CHEK1, and ABL1 — with enrichment in PI3K-Akt/mTOR and prolactin signaling pathways, and stable binding energies to CASP3 (−6.13 kcal/mol) and ESR1 (−7.68 kcal/mol). Additionally, the legumain-responsive albumin-binding prodrug WC10-003 demonstrated superior tumor growth inhibition relative to irinotecan or belotecan in xenograft models, with enhanced antitumor efficacy in combination with anti-PD-1 therapy linked to PI3K-AKT pathway suppression and a shift in tumor-associated macrophages toward a less immunosuppressive phenotype.

Lira-cel's Early Promise: A New Horizon for CAR-T in Ovarian Cancer

The journey of CAR-T cell therapy has been nothing short of revolutionary for patients battling hematological malignancies, transforming prognoses from months to years in many cases. However, translating this success to solid tumors has proven to be a formidable challenge, often hampered by issues like limited T-cell persistence and the complex, immunosuppressive tumor microenvironment. This is why the recent update on liraltagene autoleucel (lira-cel) in recurrent ovarian cancer is particularly noteworthy.

Ovarian cancer remains one of the most lethal gynecological cancers, characterized by high recurrence rates and a grim prognosis for those with recurrent disease. Against this backdrop, the Phase I data for lira-cel, showing no dose-limiting toxicities and several patients achieving over a year of survival—a stark contrast to the typical prognosis of weeks—represents a significant early signal. This suggests that lira-cel may be effectively navigating some of the inherent obstacles that have historically limited CAR-T efficacy in solid tumors.

While these early results are encouraging, the path forward for CAR-T in solid tumors is still fraught with challenges. The inherent complexities of CAR-T manufacturing, which is personalized, intricate, and costly, present a significant hurdle for scalability and broad accessibility. Furthermore, CAR-T therapies are known to induce severe adverse events, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and major adverse cardiovascular events (MACE). Although management strategies for these toxicities are improving, they can still lead to intensive care admissions and impact patient outcomes, especially in vulnerable populations.

Looking ahead, the potential for lira-cel extends beyond its direct efficacy. Research indicates that metabolic modulation, such as targeting cholesterol metabolism, can enhance CAR-T cytotoxicity in ovarian cancer. This opens the door for future combination strategies that could further optimize CAR-T performance in solid tumors. The continued development of lira-cel will be critical in determining if this early promise can translate into a durable, safe, and accessible therapeutic option, potentially ushering in a new era for CAR-T in solid tumor oncology.